What is really going on in politics? Get our daily email briefing straight to your inbox Sign up Thank you for subscribing We have more newsletters Show me See our privacy notice Invalid Email

Vital drugs for asthma, diabetes and cancer could cost up to seven times more under a UK trade deal with Donald Trump’s America, according to new analysis by Labour.

President Trump and senior members of his cabinet have said they are tired of ‘foreign freeloading.’

They say any new trade deal should bring prices into line with those in the US - which is bad news for the NHS.

Stats show the world’s top twenty best selling prescription were over three times more expensive in the US than in the UK.

(Image: Getty)

This is reflected in the US Government’s official negotiating objectives for a trade deal with the UK, which calls for ‘full-market access’ for pharmaceutical products.

And it could push the price of vital drugs up.

Academics from the University of Liverpool found:

Novorapid, a treatment for diabetes, costs seven and a half times as much in the US as in the UK, making the estimated cost of a 10ml vial £105.60, compared to £14.08 in the UK.

Spiriva, a treatment for Asthma, costs nearly six times as much, with an estimated US cost of £194.30 per 30 capsules compared to £33.50 in the UK.

Neluasta, a drug that helps fight infection during chemotherapy, is nearly three and a half times more expensive in the US.

Jonathan Ashworth MP, Labour’s Shadow Health Secretary, said: “ Boris Johnson wants to crash out of the EU without a deal and go cap in hand to his good friend Donald Trump for a trade deal that will drive up the cost of vital treatments and pave the way for US corporations to help themselves to parts of our NHS.

“Our health service is already on its knees after nine years of cuts by Conservative governments. It can’t take much more.

“Boris Johnson can’t be trusted with our NHS.”

(Image: Adam Gerrard/Daily Mirror)

The US has made a series of public statements about rebalancing drug prices.

In May, Alex Azar - the Health Secretary - said other governments should pay more for prescription drugs through trade deals.

A White House summary said the plan to lower US drug prices would target “foreign freeloading” in other countries that use “socialised healthcare to command unfairly low prices from U.S. drug makers.”

Mr Azar said: “On the foreign side, we need to, through our trade negotiations and agreements, pressure them.

“And so we pay less, they pay more. It shouldn’t be a one-way ratchet. We all have some skin in this game.”